Oryzon Genomics secured €52 million in financing from various sources between December 2024 and July 2025. This funding includes €30 million from a capital raise, commercial bank loans, an EU-IPCEI grant, and R&D cash-back incentives. The company has also expanded clinical trials for vafidemstat in several indications, including Borderline Personality Disorder, Autism Spectrum Disorder, and various oncology trials. Additionally, a new Phase II trial is being prepared to target aggression in Autism Spectrum Disorder. Furthermore, the company is making progress in expanding iadademstat into non-malignant hematological indications, with a first clinical trial in sickle cell disease.

Oryzon reported financial results for the first half of 2025, with $61 million secured in funding, including $30 million from a capital raise. The company is advancing its clinical programs with this funding and has submitted the clinical trial protocol for vafidemstat’s Phase III trial in Borderline Personality Disorder to the FDA. Oryzon is expanding its EVOLUTION trial in schizophrenia to other EU countries and is making significant progress in its oncology trials with iadademstat. Plans are also underway to evaluate iadademstat for aggression in Autism Spectrum Disorder and expand clinical evaluation into non-malignant hematological indications.

The company has been successful in securing funding and advancing its clinical programs, including expanding vafidemstat trials into new indications and geographies. Oryzon is making significant progress in its oncology trials and plans to evaluate iadademstat in non-malignant hematological indications. The financial results for the first half of 2025 reflect the company’s commitment to advancing its pipeline and delivering value to patients and shareholders.

Read more at GlobeNewswire: ORYZON Reports Financial Results and Corporate Update for